These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 15287931

  • 1. Effects of orlistat on obesity-related diseases - a six-month randomized trial.
    Guy-Grand B, Drouin P, Eschwège E, Gin H, Joubert JM, Valensi P.
    Diabetes Obes Metab; 2004 Sep; 6(5):375-83. PubMed ID: 15287931
    [Abstract] [Full Text] [Related]

  • 2. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 3. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 4. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 5. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 7. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 8. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community.
    Ostgren CJ, Merlo J, Råstam L, Lindblad U.
    Diabetes Obes Metab; 2004 Sep; 6(5):367-74. PubMed ID: 15287930
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Sep; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 10. Added benfluorex in obese insulin-requiring type 2 diabetes.
    Leutenegger M, Bauduceau B, Brun JM, Guillon-Metz F, Martin C, Nicolino-Peltier C, Richard JL, Vannereau D.
    Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
    [Abstract] [Full Text] [Related]

  • 11. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 12. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.
    Pathan MF, Latif ZA, Nazneen NE, Mili SU.
    Bangladesh Med Res Counc Bull; 2004 Apr; 30(1):1-8. PubMed ID: 15376463
    [Abstract] [Full Text] [Related]

  • 13. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 14. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Kuo CS, Pei D, Yao CY, Hsieh MC, Kuo SW.
    Int J Clin Pract; 2006 Aug; 60(8):906-10. PubMed ID: 16893433
    [Abstract] [Full Text] [Related]

  • 15. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [Abstract] [Full Text] [Related]

  • 16. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 17. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 19. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 20. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T, Samara M, Constantinidis T, Tziomalos K, Krassas G.
    Angiology; 2007 May; 58(1):26-33. PubMed ID: 17351155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.